Mumbai-based health-tech startup Qure.ai is aiming for profitability within six months as it scales its AI-driven diagnostic tools. While the company is expanding globally with multiple FDA clearances, recent financial filings show widening losses, making its shift toward sustainable operations a critical area for observers to track.
Mumbai-based health-tech startup Qure.ai has set a target to achieve profitability within the next six months. The company, which is privately held, is currently working to transition from a phase of high capital investment toward a sustainable business model by balancing its extensive global diagnostic operations with stricter cost management.
Known for its artificial intelligence-driven diagnostic tools, the firm uses platforms like qXR to process chest X-rays to identify anomalies such as tuberculosis and cancer. With 36 US FDA clearances and operations spanning over 100 countries, the company has established a significant footprint in the healthcare sector. Its business model relies on a mix of revenue from tuberculosis screening in developing regions and high-value diagnostic services for chronic diseases in developed markets.
While the company has reported revenue growth, reaching ₹190.4 crore in FY25, its financial trajectory highlights the challenges of scaling AI technology. The company’s net losses widened to ₹90.4 crore in FY25, increasing from ₹48 crore in FY24. Achieving the new break-even target will require management to improve profit margins while continuing to maintain the heavy research and development spending necessary to stay competitive in the crowded healthcare AI sector.
The firm has raised $123 million from investors including Lightspeed Venture Partners, Sequoia India, and Novo Holdings. Management has indicated that there are no immediate plans for further fundraising, signaling a strategy to optimize existing infrastructure and cash reserves. This focus on internal efficiency is often seen as a foundational step for private companies preparing for a public market debut, with industry projections frequently pointing toward a potential IPO for the company in the coming years.
For those observing the healthcare technology space, the primary monitorable will be the company’s ability to control its widening losses while simultaneously scaling new products. This includes its recent move into comprehensive patient management tools and the deployment of AIRA, a voice-enabled clinical agent designed to automate administrative tasks for healthcare providers. The success of this pivot will depend on whether the firm can increase revenue faster than its operational expenses, proving that its AI-led diagnostic model can become self-sustaining without the need for constant capital infusions.